AC Immune S.A. (ACIU) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    AC Immune S.A.

    NASDAQ: ACIU · Real-Time Price · USD
    2.20
    -0.08 (-3.51%)
    At close: Sep 08, 2025, 3:59 PM
    2.20
    0.00%
    After-hours: Sep 08, 2025, 04:10 PM EDT

    AC Immune S.A. Income Statement

    Financials in CHF. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 27.31M 14.8M 3.94M n/a
    Cost of Revenue
    		 62.57M 54.61M 60.34M 62.28M
    Gross Profit
    		 27.31M -39.8M -56.4M -62.28M
    Operating Income
    		 -52.38M -53.62M -70.85M -79.01M
    Interest Income
    		 3.2M 1.04M 69K 6.49M
    Pretax Income
    		 -50.91M -54.22M -70.74M -72.99M
    Net Income
    		 -50.92M -54.23M -70.75M -73M
    Selling & General & Admin
    		 11.43M 10.58M 15.79M 10.88M
    Research & Development
    		 62.57M 54.61M 60.34M 62.28M
    Other Expenses
    		 5.68M -51.36M -1.34M 5.85M
    Operating Expenses
    		 79.69M 13.82M 74.78M 79.01M
    Interest Expense
    		 133K 176K 355K 581K
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 79.69M 68.42M 74.78M 79.01M
    Income Tax Expense
    		 3K 10K 13K 3K
    Shares Outstanding (Basic)
    		 99.69M 84.69M 83.55M 74.95M
    Shares Outstanding (Diluted)
    		 99.69M 84.69M 83.55M 74.95M
    EPS (Basic)
    		 -0.51 -0.64 -0.85 -0.97
    EPS (Diluted)
    		 -0.51 -0.64 -0.85 -0.97
    EBITDA
    		 -48.62M -51.83M -69.05M -77.11M
    EBIT
    		 -50.78M -54.05M -70.39M -79.01M
    Depreciation & Amortization
    		 2.16M 2.21M 2.36M 1.9M

    Add to Watchlist